Te Ahumairangi Investment Management Ltd Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

Te Ahumairangi Investment Management Ltd lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the 4th quarter, Holdings Channel.com reports. The fund owned 51,065 shares of the company’s stock after buying an additional 300 shares during the period. Johnson & Johnson makes up 1.5% of Te Ahumairangi Investment Management Ltd’s holdings, making the stock its 16th largest holding. Te Ahumairangi Investment Management Ltd’s holdings in Johnson & Johnson were worth $7,385,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank purchased a new stake in Johnson & Johnson during the fourth quarter worth $4,390,037,000. Raymond James Financial Inc. purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at $1,339,878,000. Janus Henderson Group PLC raised its stake in shares of Johnson & Johnson by 228.1% during the 3rd quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock worth $549,223,000 after buying an additional 2,356,359 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock worth $33,666,460,000 after buying an additional 1,772,706 shares in the last quarter. Finally, Franklin Resources Inc. grew its stake in Johnson & Johnson by 11.4% in the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after acquiring an additional 1,729,281 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. Leerink Partners reduced their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Citigroup reduced their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 19th. Stifel Nicolaus cut their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Trading Down 7.6 %

JNJ stock opened at $153.25 on Wednesday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a market cap of $369.30 billion, a price-to-earnings ratio of 23.04, a PEG ratio of 2.56 and a beta of 0.47. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The business has a fifty day simple moving average of $159.16 and a 200-day simple moving average of $155.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.29 EPS. On average, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.24%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.